Does COVID-19 Cause Guillain-Barre Syndrome?

Introduction to the Study

A recent study published in the journal Brain investigates the potential relationship between COVID-19 and Guillain-Barré Syndrome (GBS). Since the emergence of COVID-19 in late 2019, a variety of symptoms and health complications have been reported, including neurological conditions that have raised concerns, particularly GBS.

Understanding Guillain-Barré Syndrome

GBS is characterized by an abnormal immune response that attacks the nerves, leading to symptoms such as tingling or weakness in the limbs, which can escalate to paralysis. Typically, GBS occurs several days or weeks following bacterial or viral infections.

Initial Observations

The connection between COVID-19 and GBS was first noted in late January 2020, when an asymptomatic COVID-19 patient exhibited GBS symptoms eight days post-diagnosis. This case prompted further reports of GBS onset in five additional patients following COVID-19 infection, leading researchers to explore whether COVID-19 could be a trigger for GBS or if these occurrences were coincidental.

Research Methodology

Neuroscientists at University College London conducted a detailed study to explore this link. They analyzed data from the UK National Immunoglobulin Database, focusing on GBS hospitalization cases from January 1 to May 31, 2020. This data was compared with information from previously documented cases in the European International GBS Outcome Study. Researchers examined symptoms, characteristics, and demographics of GBS patients diagnosed during the pandemic versus those diagnosed prior.

Evaluating the Association

To assess the relationship between COVID-19 and GBS, the researchers categorized cases into three groups: definite COVID-19, probable COVID-19, and non-COVID-19. A diagnosis of GBS within six weeks of a confirmed COVID-19 case was considered a definite link, while longer intervals were categorized as probable.

Findings of the Study

Between 2016 and 2019, the average annual incidence of GBS in the UK was 1,098 cases, consistent with figures from North America and Europe. During March, April, and May of 2020, daily COVID-19 infections ranged from 4,000 to 6,000. If a connection existed between COVID-19 and GBS, an increase in GBS diagnoses would be anticipated during this period. However, the study revealed a significant decrease in GBS cases during these months compared to previous years, with no regional correlation found across the UK.

Statistical Analysis

The statistical analysis indicated a likelihood of 0.016 GBS cases for every 1,000 COVID-19 infections. Ultimately, the study found no probable relationship between COVID-19 and GBS, nor any unique GBS symptoms attributable to COVID-19.

Conclusion and Future Research

While the research did not establish a definitive association between COVID-19 and Guillain-Barré Syndrome, the rare instances that have been reported warrant further investigation. Additional studies are necessary to explore these occurrences and to better understand the overall impact of COVID-19 on neurological health.

References

Uclnews. (n.d.). No association between COVID-19 and Guillain-Barré syndrome. Retrieved December 20, 2020, from https://www.eurekalert.org/pub_releases/2020-12/ucl-nab121120.php
Keddie, S., Lunn, M. P., Foster, M., Machado, P. M., Pipis, M., Mousele, C., . . . Paterson, R. W. (n.d.). Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome. Brain, 2-32. doi:10.37473/dac/10.1101/2020.07.24.20161471